跳至主要内容
临床试验/ISRCTN71502099
ISRCTN71502099进行中(未招募)3 期

Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (the ROAM trial)

The Walton Centre NHS Foundation Trust (UK)0 个研究点目标入组 157 人开始时间: 2014年5月19日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
157

研究概览

简要总结

2015 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/26576533 protocol 2020 Other publications in https://www.ncbi.nlm.nih.gov/pubmed/32045067 qualiatative analysis (added 12/02/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 03/05/2017:
  • 1. Histologically confirmed newly diagnosed solitary atypical meningioma (WHO grade II) based on the 2016 WHO criteria
  • 2. Age >/= 16 years
  • 3. All anatomical locations allowed except optic nerve sheath tumour
  • 4. Complete resection (Simpson 1, 2 or 3) as assessed by the surgeon
  • 5. Able to commence radiotherapy between within 12 weeks of surgery (ideally 8-12 weeks)
  • 6. WHO performance status 0, 1 or 2
  • 7. Women of reproductive potential must use effective contraception for the whole duration of the treatment
  • 8. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Previous inclusion criteria:
  • 1. Histologically confirmed newly diagnosed solitary atypical meningioma (WHO grade II) based on the 2007 WHO criteria
  • 2. Age 16 years or over
  • 3. All anatomical locations allowed except optic nerve sheath tumour
  • 4. Complete resection (Simpson grade I, II or III) as assessed by the surgeon
  • 5. Able to commence radiotherapy between 8 and 12 weeks after surgery
  • 6. WHO performance status 0-2

排除标准

  • Current exclusion criteria as of 05/04/2019:
  • 1. Neurofibromatosis type II (NF-2)
  • 2. Optic nerve sheath tumours
  • 3. Multiple meningiomas
  • 4. Radiation-induced meningioma
  • 5. Clinical evidence of second malignancy, except for cervix carcinoma in situ or basal cell carcinoma, and history of invasive malignancy unless treated with curative intent and the patient has been disease free for the last five years
  • 6. Previous intracranial tumour in the last 10 years treated with radiotherapy or chemotherapy
  • 7. Pregnant or lactating women.
  • Previous exclusion criteria as of 03/05/2017:
  • 1. Neurofibromatosis type II (NF-2)
  • 2. Optic nerve sheath tumours
  • 3. Multiple meningiomas
  • 4. Radiation-induced meningioma
  • 5. Clinical evidence of second malignancy, except for cervix carcinoma in situ or basal cell carcinoma, and history of invasive malignancy unless treated with curative intent and the patient has not been disease free for the last five years
  • 6. Previous intracranial tumour
  • 7. Pregnant or lactating women
  • Previous exclusion criteria:
  • 1. Neurofibromatosis type II (NF-2)
  • 2. Multiple meningiomas
  • 3. Previous radiotherapy to the brain or meninges interfering with the protocol treatment plan
  • 4. Clinical evidence of second malignancies, except a history of cervix carcinoma in situ and/or basal cell carcinoma
  • 5. Pregnant or lactating women

研究者

发起方
The Walton Centre NHS Foundation Trust (UK)

相似试验